Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company advancing cancer therapies. Company updates center on Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 receptor.
Recurring news includes quarterly financial results, product revenue for Revuforj and Niktimvo, collaboration revenue from Niktimvo commercialization with Incyte, clinical data presentations in acute leukemia, chronic graft-versus-host disease and related indications, FDA-related product updates, investor conference activity and inducement equity grants under Nasdaq listing rules.
Syndax Pharmaceuticals (SNDX) has granted inducement awards to seven new employees under its 2023 Inducement Plan. The awards consist of options to purchase up to 188,100 shares of common stock. The stock options have a four-year vesting schedule, with 25% of shares vesting after one year and the remaining 1/48th vesting monthly over the subsequent 36 months, contingent on continued employment with Syndax.
Syndax Pharmaceuticals (SNDX) has scheduled its first quarter 2025 financial results announcement and business update for Monday, May 5, 2025. The company will host a conference call and live audio webcast at 4:30 p.m. ET on the same day.
Investors and interested parties can access the webcast through the Events & Presentations page in the Investors section of Syndax's website. Alternative access is available via phone using the Conference ID: Syndax1Q25, with domestic dial-in at 800-590-8290 and international at 240-690-8800.
A replay of the conference call will be available on the company's website approximately 24 hours after the event and will remain accessible for 90 days.
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has announced inducement grants under NASDAQ Listing Rule 5635(c)(4). The company granted stock options to purchase up to 50,000 shares of common stock to four new employees under its 2023 Inducement Plan.
The stock options feature a four-year vesting schedule, with 25% of shares vesting after the first year and the remaining shares vesting monthly at 1/48th over the subsequent 36 months. Continued employment with Syndax is required through applicable vesting dates.
Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has announced its upcoming participation in the Stifel 2025 Virtual Targeted Oncology Forum. CEO Michael A. Metzger and other management team members will engage in a fireside chat scheduled for Wednesday, April 9, 2025, at 10:30 a.m. ET. The event will be accessible via live webcast through the company's website investor section, with a replay option available for a time.
Syndax Pharmaceuticals (NASDAQ: SNDX) has announced the granting of inducement awards under its 2023 Inducement Plan. The company, which focuses on developing cancer therapies, issued stock options to purchase up to 282,000 shares of common stock to 12 new employees on March 1, 2025.
The stock options feature a four-year vesting schedule, with 25% of shares vesting after the first year, followed by monthly vesting of 1/48th of the underlying shares over the subsequent 36 months. Continued employment with Syndax is required through the applicable vesting dates.
Syndax Pharmaceuticals (SNDX) reported Q4 and full year 2024 results, highlighting strong initial performance of two newly launched products. Revuforj generated $7.7 million in net product revenue in its first five weeks of launch, while Niktimvo was launched in partnership with Incyte in late January 2025.
The company reported Q4 2024 financial results with a net loss of $94.2 million ($1.10 per share). R&D expenses increased to $65.5 million, while SG&A expenses rose to $37.7 million. For full year 2024, net loss was $318.8 million ($3.72 per share).
Key developments include positive pivotal data from AUGMENT-101 trial, with plans to submit sNDA for Revuforj in R/R mNPM1 AML in Q2 2025. The company maintains a strong financial position with $692.4 million in cash and investments, which is expected to fund operations until profitability.
Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company focused on developing cancer therapies, has announced its participation in two major investor conferences in March 2025. The company's CEO Michael A. Metzger and management team members will attend the TD Cowen 45th Annual Health Care Conference in Boston on March 4, featuring a fireside chat at 3:10 p.m. ET, and the Barclays 27th Annual Global Healthcare Conference in Miami Beach on March 13, with a fireside chat scheduled for 8:30 a.m. ET.
Live webcasts of both presentations will be available on Syndax's website in the Investor section at www.syndax.com, where replays will also be accessible for a time.
Syndax Pharmaceuticals (SNDX) has scheduled its fourth quarter and full year 2024 financial results announcement and business update for Monday, March 3, 2025. The company will host a conference call and live audio webcast at 8:00 a.m. ET on the same day.
Investors and interested parties can access the webcast through the Events & Presentations page in the Investors section of Syndax's website. Alternative access is available via phone using the conference ID: Syndax4Q24, with domestic dial-in number 800-590-8290 and international dial-in number 240-690-8800.
A replay of the conference call will be available on the company's website approximately 24 hours after the event and will remain accessible for 90 days.
Syndax Pharmaceuticals (SNDX) has announced the granting of inducement awards under its 2023 Inducement Plan. The company granted stock options to purchase up to 124,000 shares of common stock to six new employees on February 1, 2025. These stock options follow a four-year vesting schedule, with 25% of shares vesting after the first year, followed by monthly vesting of 1/48th of the underlying shares over the subsequent 36 months. The vesting is contingent upon continued employment with Syndax.